Condition

mCRPC clinical trials and research

• 11Clinical trials
• 16NIH research projects
• 1New in 30 days
• 7Countries

Newest mCRPC clinical trials

All recruiting trials (11)

• AXT-1003 plus Enzalutamide in advanced prostate cancer

  This study tests whether adding AXT-1003 to Enzalutamide helps men with advanced prostate cancer stay disease-controlled or improve outcomes.

  Recruiting at 2 sites Phase 1 Axter Therapeutics (Beijing) Co., Ltd · Guangzhou, Guangdong and 3 other locations · NCT07897071

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

• Lower-dose ARPI therapy for metastatic prostate cancer

  This trial tests whether using half the usual dose of ARPI therapy can work as well as a full dose for men with metastatic prostate cancer who are also receiving standard hormone therapy.

  Recruiting at 4 sites Phase 3 University College, London · Huddersfield and 3 other locations · NCT07751133

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• AKY-2519 (B7‑H3 targeted radioligand) for metastatic castration‑resistant prostate cancer

  This trial tests whether AKY‑2519, a B7‑H3–targeted radioactive medicine used for imaging and treatment, is safe and can shrink tumors in men with metastatic castration‑resistant prostate cancer, including those who have had prior 177Lu‑PSMA‑617.

  Recruiting at 8 sites Phase 1 Aktis Oncology, Inc. · Irvine, California and 7 other locations · NCT07581184

• KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer

  This trial tests whether KTX-2001, by itself and combined with darolutamide, can help men whose prostate cancer has spread and stopped responding to hormone therapies.

  Recruiting at 13 sites Phase 1 K36 Therapeutics, Inc. · San Francisco, California and 12 other locations · NCT07103018

• Treating metastatic prostate cancer with [177Lu] Lu-PSMA-XT injection

  This trial tests a radioactive PSMA-targeting injection called [177Lu] Lu-PSMA-XT in men with metastatic castration-resistant prostate cancer to see if it is safe, tolerable, and can help control the cancer.

  Recruiting at 3 sites Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07096128

• Disitamab vedotin plus abiraterone for HER2-expressing metastatic castration-resistant prostate cancer

  This trial tests whether adding the antibody–drug conjugate disitamab vedotin to abiraterone helps men with HER2-expressing metastatic castration-resistant prostate cancer.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07093866

• Radium-223 treatment for prostate cancer with bone metastases

  This study is testing if Radium-223 treatment can help men with prostate cancer that has spread to their bones and whether certain scans and blood tests can predict how well the treatment works.

  Recruiting at 4 sites The Netherlands Cancer Institute · Amsterdam, North Holland and 4 other locations · NCT06659926

• Treatment for advanced prostate cancer using Lutetium-177

  This study is testing a new treatment using Lutetium-177 for men with advanced prostate cancer that hasn't responded to other therapies to see how safe it is and how well it works.

  Recruiting at 20 sites Phase 1/2 Blue Earth Therapeutics Ltd · Miami, Florida and 20 other locations · NCT05413850

• Evaluating HC-1119 for advanced prostate cancer

  This study is testing if a new medication called HC-1119 can help men with advanced prostate cancer who haven't had success with other treatments feel better compared to a placebo.

  Recruiting Phase 3 Hinova Pharmaceuticals Inc. · Shanghai · NCT03851640

NIH-funded research (16)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Dual Targeting of B7-H3 in metastatic prostate cancer

  A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11418390

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• Extending Benefit by Targeting Resistant Lesions in mCRPC

  A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11398992

• CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer

  A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11370143

• Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer

  A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11360691

• Targeted radiation approach for prostate cancer without continuous castration

  A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.

  NIH research VA Greater Los Angeles Healthcare System · Los Angeles, United States · NIH-11300187

• Liquid biopsy test to guide HER2-targeted therapy for advanced prostate cancer

  A new liquid biopsy test using blood markers to pick and guide HER2-directed therapy for men with advanced, treatment-resistant prostate cancer.

  NIH research U.s. Dept/vets Affairs Medical Center · Washington, United States · NIH-11300143

• Targeting treatment‑resistant spots to extend benefit in advanced prostate cancer

  This project finds resistant tumor spots with advanced PET/CT imaging and uses focused radiation to help men with metastatic castration‑resistant prostate cancer stay on effective systemic therapy longer.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11184192

• A newly discovered heavily methylated form of advanced prostate cancer

  Researchers are looking at a newly found heavily methylated type of advanced prostate cancer to find markers and possible weak points for treatment in men with metastatic castration‑resistant prostate cancer.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11181255

• Improving PSMA-RPT Treatment for Advanced Prostate Cancer

  This project aims to find better ways to make a special radiation treatment called PSMA-RPT work more effectively for patients with advanced prostate cancer.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11122259

• A new treatment for advanced prostate cancer that has stopped responding to abiraterone.

  This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11114019

• Targeted radiation treatment for advanced prostate cancer without hormone therapy

  This study is looking at a new way to treat advanced prostate cancer by using targeted radiation therapy that allows men to keep their testosterone levels normal, with the hope of improving their quality of life while fighting the cancer.

  NIH research VA Greater Los Angeles Healthcare System · Los Angeles, United States · NIH-11046544

• Predicting treatment outcomes for men with advanced prostate cancer using genetic information

  This study is looking to help men with advanced prostate cancer figure out if they will benefit from certain hormone therapies, so they can get the right treatment and avoid side effects from medications that might not work for them.

  NIH research Duke University · Durham, United States · NIH-11009561

• Targeting resistant lesions in advanced prostate cancer to improve treatment outcomes

  This study is looking at men with advanced prostate cancer who are not responding well to their current treatments, and it aims to find and target the stubborn areas of cancer that aren't improving, using special imaging and focused radiation therapy to help make the overall treatment more effective.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10899413

• Improving treatment effectiveness for advanced prostate cancer

  This study is looking at how to make a special cancer treatment work better for men with advanced prostate cancer by understanding the genes and immune responses of their tumors, so they can improve results and help prevent the cancer from coming back.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-10886513

• Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies

  This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-10884438

Related topics

Quick answers

How many mCRPC clinical trials are recruiting right now?

11, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in China (4 trials), United States (4 trials), Netherlands (2 trials), United Kingdom (2 trials), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 3: 3, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →